Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment by Xu, Yan
cancers
Review
Lysophospholipid Signaling in the Epithelial Ovarian
Cancer Tumor Microenvironment
Yan Xu
Department of Obstetrics and Gynecology, Indiana University School of Medicine, 1044W. Walnut Street
R4-W037, Indianapolis, IN 46202, USA; xu2@iu.edu
Received: 4 June 2018; Accepted: 5 July 2018; Published: 9 July 2018


Abstract: As one of the important cancer hallmarks, metabolism reprogramming, including lipid
metabolism alterations, occurs in tumor cells and the tumor microenvironment (TME). It plays an
important role in tumorigenesis, progression, and metastasis. Lipids, and several lysophospholipids
in particular, are elevated in the blood, ascites, and/or epithelial ovarian cancer (EOC) tissues,
making them not only useful biomarkers, but also potential therapeutic targets. While the roles
and signaling of these lipids in tumor cells are extensively studied, there is a significant gap in our
understanding of their regulations and functions in the context of the microenvironment. This review
focuses on the recent study development in several oncolipids, including lysophosphatidic acid and
sphingosine-1-phosphate, with emphasis on TME in ovarian cancer.
Keywords: lipids; lysophospholipids (LPLs); lysophosphatidic acid (LPA); sphingosine-1-phosphate;
tumor microenvironment (TME); epithelial ovarian cancer (EOC)
1. Introduction
The tumor microenvironment (TME) for epithelial ovarian cancer (EOC) is rather unique. It
is mainly confined within the peritoneal cavity and frequently associated with ascetic fluid [1–6].
The TME consists of many stromal cell types including: tumor-associated macrophages (TAMs),
T cells (e.g., regulatory T cells), tumor associated fibroblasts (TAFs), mesothelial cells, adipocytes,
endothelial cells (ECs), myeloid-derived suppressor cells (MDSCs), pericytes, platelets, extracellular
matrix components (EMCs), and cell-free factors [1–6].
The presence of ascetic fluid provides a mobile, easy access, and more dynamic environment
for tumor–stromal interactions. In addition to tumor and stromal cells, EOC ascites is rich in
cell-free inflammatory cytokines, chemokines, matrix metalloproteinases, integrins, and other secreted
molecules, including bioactive lipid factors. These factors are generated by and mutually function
in both tumor and stromal cells via autocrine/paracrine mechanisms. They may exist in either
extracellular vesicles (EVs) or in “free” forms, including bond forms to proteins or other molecules [7].
EVs are membrane surrounded structures released by cells in an evolutionally conserved manner, but
their release, contents, and/or up-take may be abnormally regulated in cancer. The major populations
include microvesicles (MVs, 100–1000 nm), exosomes (30–100 nm), and apoptotic bodies [8]. Exosomes
have emerged as new as diagnostic markers, as well as cell-to-cell communication vehicles, with
therapeutic applications [4,9,10]. The compositions of exosomes from different cell types are complex,
containing ~200 lipids, >3000 proteins, ~1600 mRNA and ~800 microRNAs [11–13].
Metabolic reprogramming is one of the major cancer hallmarks [14] that is critical for cancer cells
to adapt to stress from TME and the increased nutritional requirements during their growth. These
modifications occur through cross-talk between tumor and stroma cells in TME in a dynamic network
that connects different molecular processes, such as energy production, inflammatory response, and
drug resistance [15]. In particular, primary EOC is characterized by abnormal lipid metabolism and
Cancers 2018, 10, 227; doi:10.3390/cancers10070227 www.mdpi.com/journal/cancers
Cancers 2018, 10, 227 2 of 19
energy disorders. In addition, recurrent EOC patients have been shown to have increased amino acid
and lipid metabolism compared with primary EOC patients [16].
Compared to other major living cell components, including DNA, RNA (all composed by
four bases), proteins (all composed of 20 amino acids), and carbohydrates (all have the basic element
CH2O with ring, chain, and branched structures), lipids are very diverse in both their respective
structures and functions. These diverse compounds are grouped into classes; glycerophospholipids
(PLs) (including lysophospholipids (LPLs)) sphingolipids, sterol lipids, prenol lipids, saccharolipids,
and polyketides [17]. The functional involvement of many of these lipids in EOC, PLs, LPLs,
sphingophospholipids (SPLs), fatty acids, cholesterol, vitamins, and triglycerides (TGs) in particular,
have been covered by many reviews [3,18–23]. This review will focus on recent development of
signaling LPLs with an emphasis on TME in EOC.
2. LPLs
Compared to PLs, which have two fatty acid chains, LPLs only have one fatty acid chain and thus
have reduced hydrophobicity (Figure 1). In addition, many LPLs are either negatively or positively
charged, increasing their polarity and solubility in water. With these chemical properties, LPLs are
synthesized and/or secreted extracellularly and many of them function as signaling molecules through
their specific membrane receptors. In addition, several of these LPLs have tumor promoting activities
and are thus termed as “oncolipids” [24]. They are accumulated in the TME. LPA is a prototype of the
LPL signaling molecules. It exhibits pleiomorphic functions in almost all cell lineages tested. Since our
early report on LPA’s effect in EOC [25,26], more than 1000 papers have been published reporting the
roles and signaling mechanisms of LPA in various cancer types [24,27].
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Figure 1. Structures of glycerophospholipids (PLs), lysophospholipids (LPLs only have R1 or R2) and
the action sites of phospholipases.
2.1. LPA
Lysophosphatidic acids (LPAs) are a group of compounds with various fatty acid side chains,
differing in their length (commonly 14–22 carbons) and number of double bonds (commonly from zero
to six in most tissues). In addition, the chemical linkages of the fatty acid chain to the glycerol backbone
can be differently grouped as acyl-, alkyl-, and alkenyl-LPAs [28]. We have originally identified LPA as
an EOC growth factor, termed ovarian cancer activating factor [26,29]. Numerous papers have now
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been published to show that LPA induces a broad range of tumor promoting activities in EOC and
LPA is a therapeutic target for EOC [30–32].
2.1.1. Increased LPA Levels in EOC
We have initially reported LPA as a potential marker for EOC [33]. Blinded [34] and numerous
independent studies have confirmed that LPA is elevated in the blood from EOC patients, when
compare to those with benign diseases and/or healthy controls [35–42]. The mean values of
physiological and pathologic concentrations of plasma LPA in healthy women and EOC patients
are 0.6–0.9 µM and 2.0–22 µM, respectively [33,34]. The mean values of benign and malignant
ascites acyl-LPA concentrations are 2.9 µM and 19–95 µM, respectively [28,43]. The mean non-acyl
(both alkyl-, and alkenyl)-LPA levels are 3.7 ± 1.7 and 0.9 ± 0.7 µM for benign and malignant ascites,
respectively [28] (Table 1). The concentrations of LPA and other lipids mentioned below were measured
in cell-free plasma or ascites. In most reports, it is unclear whether these lipids are associated with
MVs, as mentioned in the Introduction, in a protein bound, or a “free” form. In an attempt to
test this, we have separated different MVs and the cell- and vesicle-free (S4) portion of ascites via
step-wise centrifugation. We found that human EOC ascites S4 portion potently promotes proliferation,
migration, and invasion of human EOC cells in a PLA2-dependent manner, suggesting that LPA, and
maybe other LPLs, may present in a protein bound or a “free” form [44]. However, this issue needs to
be more systematically investigated and lipid association with different extracellular components may
also be cell-type and context dependent.
The challenges to move LPA or other lipid molecules as cancer markers into clinics are several fold.
First, as metabolites, these molecules have quick turnover times by their producing and degradation
enzymes. In addition, their levels are likely to be affected by other physiological/pathologic
conditions—such as diet, smoking, and drinking—which have not been completely investigated.
Secondly, due to their chemical properties, the different extraction, storage and detection
conditions/methods used in different labs significantly affect the levels detected. However, there
are no standard procedures established. Finally, the best detecting method for these lipid markers is
electrospray-mass spectrometry (ESI-MS), which is not a routine setting in clinics currently. These
challenges have made cross-examination and validation of these markers difficult. Studies to
standardize the procedures of collection, extraction, storage, and measurements of lipid marker
are critical. Nevertheless, technique advancements are emerging. In particular, mass spectrometry will
likely become a routine technique in regular clinic settings in the near future.
2.1.2. LPA Production and Regulation
LPA is produced from secreted enzymes from lysophosphatidylcholine (LPC) by autotaxin (ATX),
as well as phospholipase A2 (PLA2) by either providing the substrate LPC for ATX, or directly produce
LPA from phosphatidic acid (PA) [49–53]. LPA is degraded outside cells by a family of three enzymes
called the lipid phosphate phosphatases (LPPs) (Figure 1). Imbalanced expression and/or activity
levels of ATX, PLA2s, and/or LPPs are involved in EOC [54] (see Figure 1 in [54]). The ATX/LPA axis
has received increasing interest as a target in cancers, fibrotic diseases, autoimmune diseases, arthritis,
chronic hepatitis, obesity, and impaired glucose homeostasis [55]. At least one of the synthetic ATX
selective inhibitors is in clinical trials for idiopathic pulmonary disease [55].
EOC cells may produce LPA upon stimulations [50–52]. However, the tissues and cells in EOC
TME are likely to be the major source of elevated LPA in EOC. The cell types involved in LPA
production include, but are not limited to, platelets, adipocytes, mesothelial cells, and immune cells.
Platelet activation generated LPA used to be considered the major source of plasma LPA [56,57].
Paraneoplastic thrombocytosis has been recognized as a prevalent phenomenon in patients with
ovarian cancer since the early 1970s [58]. Cancer patients have a ~4-fold increased risk of
venous thromboembolism compared with the general population and this is associated with
significant morbidity and mortality [59,60]. The preventative and therapeutic significance of
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blocking thrombopoietic factors (cytokines and lipids) have been noted as an interesting direction
in EOC research [60–62]. Tumor cells hijack platelet functions by activating them though platelet
aggregation [63]. Activated platelets may help tumor cells survive immune surveillance by acting as
protective “cloaks” against immune destruction. However, the major tumor cell beneficiary activities
are likely mediated by the factors secreted from platelets after activation. These factors include
cytokines (such as interleukin-6 (IL-6)), TGF-β, and lipid factors, which mediate the inflammatory,
proliferative, and proangiogenic activities of platelets to promote tumor growth, tissue invasion,
and metastasis [63]. Increased platelet counts and platelet activation associated with EOC are likely
to be important contributors for the elevated LPA levels in EOC TME. In addition, LPA promotes
platelet aggregation [64,65] and blocking platelet function leads to inhibition of metastasis of breast
cancer through decreased LPA signaling. ATX is detected in platelet α-granules. Functionally active
ATX is eventually released following tumor cell-induced platelet aggregation, thereby promoting
metastasis [66].
EOC cells preferentially metastasize to omentum, the adipose tissue, which secretes many
chemotactic cytokines and growth factors, including LPA [67–69]. Adipocytes promote ovarian
cancer metastasis and provide energy for rapid tumor growth [70]. Since the identification of ATX as
the major LPA producing enzyme [21,71] and studies conducted using mouse ATX knockout models,
it has become clear that adipose tissue are at least one of the major tissues in EOC TME that produces
LPA [72,73]. Approximately 40% of body ATX is produced by adipocytes, and this is further increased
by inflammation [74,75]. The use of ATX inhibitors seems an attractive strategy to produce novel
medicinal agents, for example anticancer agents [55].
EOC cells that metastasize within the peritoneal cavity wall and the organs enclosed are coved
by a layer of peritoneal mesothelial cells. We have shown that human peritoneal mesothelial
cells constitutively produce LPA, which accounts for a significant portion of the chemotactic
activity of the conditioned medium from peritoneal mesothelial cells to ovarian cancer cells [76].
The calcium-independent phospholipase A2 (iPLA2), and cytosolic PLA2 (cPLA2) are involved in this
production and LPA’s tumor promoting activities [76].
Although many types of immune and endothelial cells are involved in EOC TME, their
contributions to LPA production and/or degradation are less known. Steady-state ATX is expressed
by only a few tissues, including high endothelial venules in lymph nodes, but inflammatory signals
(enriched in EOC TME) can upregulate ATX expression in different tissues [77]. In addition, when
ECs are con-cultured with EOC cells, coherent and non-cell line specific changes in fatty acids,
glycerophospholipids, and carbohydrates, induced by endothelial cell contact are observed over
time [78]. Wong and Reinartz et al. have reported that macrophage-derived phospholipase PLA2G7,
which may produce extracellular LPA, is involved in EOC and associated with early relapse of EOC.
It is a secreted enzyme that may produce LPA and arachidonic acid [79,80].
Mice with homozygous deletion of LPP1 (a LPA degradation enzyme) in stromal cells result in
elevated levels and decreased turnover of LPA in vivo. In turn, enhanced tumor seeding in the LPP1
KO mice compared to wild type was observed [81].
Taken together, the host cells play an important role in producing and degradation LPA, which
may be present in cell free forms in either exosome and/or EV-free forms [44].
2.1.3. Major Cellular Functions and Signaling Mechanisms of LPA in EOC
LPA stimulates almost every aspects of tumor promoting activities, including cell proliferation
or differentiation, prevents apoptosis induced by stress or stimuli, induces platelet aggregation
stimulates cell morphology changes, cell adhesion, cell migration, and cell invasion. It also stimulates
tumorigenesis and metastasis in vivo [25,26,30–32,50,51,76,82–99].
LPA regulates many pro-tumorigenic and pro-inflammatory factors, including vascular
endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), urokinase plasminogen
activator, IL-6, IL-8, CXC motif chemokine ligand 12/CXC receptor 4, COX2, cyclin D1, Hippo–YAP,
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and growth-regulated oncogene alpha. These regulations are at the transcriptional, translational,
and epigenetic levels [19,34,44,51,76,82–84,86,88–91,94,95,100–105]. LPA induces loss of junctional
β-catenin, stimulates clustering of β1 integrins, and enhances the conformationally active population
of surface β1 integrins. Furthermore, LPA treatment initiates nuclear translocation of β-catenin and
transcriptional activation of Wnt/β-catenin target genes, resulting in gain of mesenchymal marker
expression [106]. Gglycodelin, a glycoprotein, is over-expressed in various malignancies, including
EOC, and its expression correlates with the diagnosis and prognosis of cancer patients. The expression
of glycodelin can be regulated by stromal cells and LPA [107]. While LPA’s function and signaling in
EOC has been rather extensively reviewed [19,100,108], several notions and recent developments are
specifically noted here.
Firstly, LPA is a confirmed mitogen in many cell types. However, MTT dye reduction is not a good
method to measure this effect. LPA affected MTT dye reduction with an unknown mechanism in EOC
cells [109], making it an unreliable indicator for cell number changes. In addition, MTT dye reduction
may not be sensitive enough to detect DNA replication as [3H]tymidine incorporation [25,26,29].
Secondly, the most potent roles of LPA in EOC and other cancer cells are likely to be cell migration
and invasion. This action is mediated by LPARs and Gi and G12/13 [30,51,76,83,89,95,104]. This
is correlated to LPA’s in vivo effects, where LPA mainly stimulates metastasis, instead of primary
tumor growth [89,95]. In comparison, EGF and other growth factors are likely to be more effective
in cell proliferation than LPA, but the latter is more effective in induction of cell migration and
invasion [30,51,89,90,93,95].
Thirdly, LPA has been recently shown to be involved in cancer stem cells (CSC) in EOC [84,110].
Seo et al. have shown that EOC CSC produces LPA, which augments CSC characteristics
such as sphere-forming ability, resistance to anticancer drugs, tumorigenic potential in xenograft
transplantation, and high expression of CSC-associated genes, including OCT4, SOX2, and aldehyde
dehydrogenase 1 (ALDH1). These actions are mediated by LPAR1. ATX is highly secreted from ovarian
CSCs. Inhibition or knockdown of ATX markedly attenuates the LPA-producing, tumorigenic, and
drug resistance potentials of CSCs. In addition, clinicopathological analysis shows a significant survival
disadvantage of patients with positive staining of ATX. In addition, LPA is involved in the crosstalk
between CSC in TME. EOC cells secrete LPA that activates the expression and secretion of CXCL12 by
mesenchymal stem cells (MSCs), enhancing the resistance of OVCA cells to hyperthermia [23].
Fourthly, the majority of LPA signaling is mediated by its six G protein couples receptors
(GPCRs) [100,111]. Among them, LPAR1–3 belong to the endothelial differentiation gene (Edg) family
of GPCR and LPAR4–6 belong to the purinergic P2Y family of GPCRs [111,112]. While LPAR1–3 in
general mediate LPA’s tumor promoting activities [76,113,114], limited reports showed that LPAR1
may represent a negative regulatory LPA receptor inducing apoptosis in ovarian cancer cells [96].
At least three compounds blocking these receptors have passed phase I and phase II clinical trials [115].
Compared to LPAR1–3, LPAR4–6 are less studied. Both pro- and anticancer effects mediated by LPA4–6
in various cancers have been reported, with the majority of them reporting anti-cancer effects [116–118].
Finally, LPA has also been identified as a ligand for the nuclear receptor peroxisome
proliferator-activated receptor gamma (PPARγ) [119,120]. However, the LPA-PPARγ studies are
mainly limited to the vascular and metabolic processes [121,122]. The roles of PPARγ-mediated LPA
effects in cancer are essentially unknown until recently. Emerging evidence, however, suggest that this
is an important missing opportunity in cancer research. We have recently shown that LPA dose- and
time-dependently upregulated SOX9 in EOC cells. This upregulation is mediated by PPARγ. SOX9
was involved in cellular activities related to Cancer Stem Cells (CSC), including anokis-resistance,
regulation of CSC marker CD44, and spheroid-formation [85]. In addition, we have shown that LPA
effectively upregulates ZIP4 (a zinc transporter) expression via by PPARγ and LPA’s promoting effects
in CSC-related activities in HGSOC cells is at least partially mediated by ZIP4 in an extracellular
zinc-independent manner [84]. These findings emphasize the importance of targeting by PPARγ for
LPA’s tumorigenic actions.
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2.1.4. LPA in the Immune System
The ATX-LPA axis has emerged as a novel regulator of lymphocyte homing and inflammation.
LPARs are expressed by T cells and LPA enhances the motility of human and mouse T cells in vitro,
although generally not in a direct manner [77]. Cancer cells must evade the immune system during
metastasis. LPA facilitates this important process by inhibiting CD8+ T cell activation [75]. LPA also
regulates macrophage differentiation and T cell motility [123,124]. Although EOC cells mainly express
the LPAR1–3, LPAR6 is the main LPA receptor on TAM and tumor-associated T cells [123].
ATX is expressed by lymphoid organ high endothelial venule. LPARs receptors are expressed by
NK cells, mast cells, eosinophils, and B cells [77]. In addition, tumor-associated macrophages (TAMs)
produce LPA [123]. However, how LPA signaling in stroma cells, and in immune cells in EOC in
particular, remains to be further investigated.
In summary, LPA, a simple molecule that mediates a plethora of biological effects, may be
targeted at its levels of production by ATX or PLA2s, LPA receptors, including PPARγ, or through
LPA degradation by lipid phosphate phosphatases (LPPs). The targeting strategy should take TME
into serious consideration. Drugs for these applications have been and will soon be entering clinical
practice [27].
2.2. LPC
Compared to LPA, plasma LPC levels are usually 10 to 100-fold higher and are in the 100–200 µM
range in human subjects [34] (Table 1). LPC levels have been shown to be significantly elevated
in the plasma of ovarian cancer patients [34,125,126]. On the other hand, others and we have
shown that patients with malignant cancer diseases have attenuated LPC plasma levels [127–131].
Moreover, different phospholipase A2 enzymes, which mainly convert phosphatidylcholine (PC) to
LPC have been shown to be functionally involved in EOC and/or as markers for various cancer
types [7,44,50,51,91,126,132,133].
LPC is present at the highest concentrations among LPLs. Its role in signing is still debatable.
Although both of its tumor-promoting and suppressing activities have been reported in various
cancers [96,129,134,135], specific attention should be paid that LPC is not present in a free form in
most physiological and pathologic conditions. It binds to albumin and other carrier proteins [136,137].
The bound form of LPC may not have many of the effects reported previously [91,137]. In particular,
when high concentrations (>20 µM) of free LPC are used, it may have non-specific and detergent-like
effects, which are unlikely to be physiologically or pathologically significant. LPC may function as a
component of cell membrane and carrier to deliver choline to tissues and LPC is the precursor/substrate
for ATX to produce LPA. However, its levels are hardly rate-limiting. This fact is also pertinent to
developing ATX inhibitors. Those ATX substrate analog inhibitors are difficult to work in vivo, due to
the competitive high concentrations of LPC present in the human blood and/or other tissues.
Table 1. Concentrations (in µM) of major lysophospholipids (LPLs) involved in epithelial ovarian
cancer (EOC).
Lipid EOC or BC Plasma Healthy Control Plasma EOC Ascites Benign Ascites
Acyl-LPA 2–22 [33,34] 0.6–0.9 [33,34] 19–95 [28,43] 2.9 [28,43]
Alkyl-, and alkenyl-LPA 3.7 ± 1.7 [28] 0.9 ± 0.7 [28]
LPI to 3.0 [28,35] 0–1.5 [28,35] 14.7 ± 9.7 [28,35] 2.9 ± 2.0 [28,35]
LPC 120 ± 0.30 [45]117–153 [34]
128 ± 46 [45]
122 [34]
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2.3. Lysophosphatidylinositol (LPI) and Other LPLs
While phosphatidylinositol (PI) is the substrate of PI3K, one of the most pertinent signaling
pathways in cancer [138], LPI as a signaling molecule is much less studied. We have shown that
the plasma and ascites levels of LPI in EOC are elevated. In healthy controls, the plasma levels of
LPI are in the range of 0–1.5 µM in healthy subjects, which are increased to 1.1–3.0 µM in patients
with EOC [28,35]. The means and SDs levels of LPI in non-malignant ascites vs. malignant EOC
are 2.9 ± 2.0 µM and 14.7 ± 9.7 µM respectively (Table 1). However, in our lab, unlike LPA and
sphingosine-1-phosphate (S1P), neither positive nor negative effects of LPI have been detected in EOC
cells. A very recent report has shown that LPC and LPI regulate gene expression, including adhesion
molecules, cytokines, and chemokines, as well as those involved in cholesterol biosynthesis (by LPC),
or gene transcripts critical for the metabolism of glucose, lipids, and amino acids (by LPI) in human
aortic endothelial cells (HAECs). Moreover, LPC and LPI share the ability to transdifferentiate HAECs
into innate immune cells [139].
Although a specific receptor of LPI has been reported [140], they warrant further validation
for their rules and signaling in cancers. We and others also detected several other LPLs in EOC
plasma and/or ascites, including lysophosphatidylethanolamine (LPE), lysophosphatidylglycerol
(LPG), lysophosphatidylserine (LPS), lyso-platelet activating factor (lyso-PAF), and PAF [28,35,45,141].
However, the role and signaling of these LPLs in EOC are much less studied.
2.4. Sphingosine-1-Phosphate (S1P)
2.4.1. S1P Levels and Production
S1P is the orthologue of LPA with a different backbone (a sphingoid base vs. a glycerol backbone).
The physiological and pathologic concentrations of S1P is approximately one order of magnitude
lower than that of LPA and is usually present in sub-µM to low µM range [45–48] (Table 1).
In contrast to LPA, S1P is mainly produced intracellularly by two sphingosine kinases
(SphK1 and SphK2; see Figure 1 in [142] and Figure 2 in [143]). S1P may be irreversibly degraded by
S1P lyase (SPL) or dephosphorylated by S1P phosphatases (SPPs). Since the S1P lyase level in the blood
was much lower than that in tissues and erythrocytes, as well as platelets lack SPL and SPP activity
when they mature, higher S1P levels in the blood and lower amounts in tissues are present [144].
Intracellularly produced S1P is exported out of the cell either by the specific transporter Spinster
2 (Spns2) or by several members of the ABC transporter family [145]. This autocrine and/or paracrine
action of S1P is known as “inside-out signaling”. In the last few years, it has become evident that
S1P also exerts intracellular functions by targeting different molecules, including the PPARγ family
factors [145].
2.4.2. S1P Functions and Signaling Mechanisms in EOC
Over the past two decades, increasing evidence demonstrates a strong link between S1P and both
normal physiology and progression of different diseases, including cancer and inflammation. S1P may
affect survival, proliferation, angiogenesis, and metastatic spread of cancer [144,146].
LPA and S1P share structural similarity. In addition, LPAR1–3 and S1PR1–5 belong to the same
edg-receptor family [147]. Moreover, S1P has been shown to have many similar tumor promoting
activities as LPA, and is considered as a cancer treatment target [148,149], which has been reviewed
extensively [32,144,146,150,151] (Figure 2). However, there are several major differences between LPA
and S1P. Most of all, while LPA displays, in most cases, tumor promoting activities; S1P is multi-facet
at several levels, which is emphasized as follows.
Firstly, S1P has strong concentration dependent differential effects. As mentioned above, the
physiological/pathological concentrations of S1P are in general lower than those of LPA [46–48].
The effects of S1P in EOC cells tested are highly concentration-dependent [152–157]. While lower
concentrations of S1P (≤1 µM) are usually stimulatory, higher concentrations (10–30 µM) of S1P are
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inhibitory. The S1P effects are also dependent on cell culture conditions. For example, S1P (10 µM)
induced cell death when cells were in suspension but stimulated cell growth when cells were attached.
The calcium-dependent induction of cell death by S1P is apparently associated with its inhibitory effect
on cell attachment and cell adhesion [152]. N-cadherin, γ- and β-catenins, FAK, and integrin β1 are
among the proteins affected by S1P and/or LPA [152,156].
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Figure 2. Diagram illustration of LPA receptors, signaling pathways and functions shown in EOC.
LPA stimulates almost every aspect of tumor promoting activities [24,25,29–31,44,45,70,77–94]. This figure
illuminates updated information related to LPA receptors (LPAR1 to LPAR6, and PPARγ), signaling
pathways, and functions shown in EOC, modified from a previous review article by Yung et al. [94].
In particular, the nuclear receptor for LPA, PPARγ is included. While Gα12/13, Gαq, and Gαi mediate
tumor promoting activities in most cases, Gαs is likely to be a negative regulator counter-reacting Gαi
actions. Abbreviations: autotaxin (ATX); LIM kinase (LIMK); lysophospholipids (LPLs); myosin light
chain (MLC) phosphatidic acid (PA); phospholipids (PLs); phospholipase D (PLD); phospholipase A1
(PLA1); and phospholipase A2 (PLA2).
Cancers 2018, 10, 227 9 of 19
Based on chemically measured S1P concentrations in biological fluids and the binding affinities of
S1P to its receptors (in nM to low µM range [158]), the effects of low concentrations of S1P (≤1 µM)
may be more pathophysiologically relevant. The effects of high concentrations of S1P (10–30 µM) may
be more artificial and/or non-specific.
Secondly, SphK1 and SphK2 have distinct cellular locations, regulations and functions. In general,
SphK1 is tumor promoting and SphK2 is suppressive; SphK1 is upregulated in cancer, while SphK2
is downregulated [151,159,160]. Numerous tumor promoting agonists including TNF-α and other
inflammatory signaling molecules, such as IL-1β, IFN-γ, IgE, and C5a, stimulate cytosolic SphK1,
which translocates to the plasma membrane and uses sphingosine as a substrate to generate S1P.
Elevated SphK1 has been shown in EOC cells and functionally involved in drug-resistance and other
tumor promoting activities [161,162]. In contrast, SphK2 is located in cytosol or in the nucleus [144].
S1P produced by SphK2 inhibits histone deacetylases (HDACs), which modulates the dynamic balance
of histone acetylation and influences the epigenetic regulation of specific target genes [163]. The two
SphKs are also likely to have cooperative roles as evidence by knockout mice. Double-knockout
animals were embryonic lethal, due to the incomplete maturation of the vascular system and brain,
although mice deficient in either SphK1 or SphK2 had no obvious abnormalities [151].
Thirdly, different and opposing effects are mediated by different S1PRs. S1P receptors have
been identified so far and named S1PR1–5 (formerly referred to as endothelial differentiation gene
(Edg1, 5, 3, 6, 8) [147]. Following receptor activation, multiple signaling cascades are activated, which
are very similar to or opposing to those stimulated by LPA [164,165]. Among the five S1PRs,
S1PR1/S1PR3 and S1PR2 receptors may mediate opposing effects [149,151,153,154,157,159,160]. S1PR1
and S1PR3 mediate S1P’s tumor promoting activities, such as cell migration and invasion via activation
of Rac. Blockage of SphK1, but not SphK2, or S1PR1/3 could attenuate ovarian cancer angiogenesis and
inhibit angiogenic factor expression in a mouse model [159]. S1PR1 is upregulated in ovarian cancer
tissues and cell lines, which is negatively regulated by miR-148a in EOC cells [166]. On the other
hand, S1PR2 generally mediates the inhibitory effect via Rho-mediated inhibition of Rac [160]. S1PR2
is also involved in negative regulation of tumor angiogenesis and tumor growth in vivo via RhoC
activation [167], although one study has shown that the growth of SKOV3 cells could be decreased
by S1PR2 inhibition in vitro and in vivo [168]. In addition, S1PR2 has an inhibitor role in macrophage
recruitment during inflammation [169]. Goetzl et al. reported that both S1PR2 and S1PR3 are expressed
higher in ovarian surface epithelial cells than in ovarian cancer cells [170].
Finally, S1P may have profound regulator effects on inflammation and in the immune system.
The SphKs/S1P/S1PR1 axis plays an important role in the immune regulation. It is involved in the
mature vascular system; pathological angiogenesis; immune cell egress from tissue compartments;
hematopoietic, vascular, and stem cell survival; and cytokine production. In particular, S1P induces
STAT3 activation in tumor-associated myeloid derived suppressing cells (MDSCs) [151]. In addition,
the roles of LPA and S1P on angiogenesis are likely to be different. S1P may have a direct proangiogenic
role on ECs [159]. S1P and its receptors are involved in vessel morphogenesis and angiogenesis
during embryonic development and in the adult organism both under normal and pathological
conditions [171,172]. On the other hand, LPA’s role on ECs may be indirect and mediated by its effect
on tumor and/or TME cells via releasing proangiogenic factors, such as IL-8 [92,94,173].
SphK1 is highly expressed in the tumor stroma of high grade serous ovarian cancer (HGSOC)
and is required for the differentiation and tumor promoting function of cancer-associated fibroblasts
(CAFs) [174]. While increasing S1P catabolism or inhibiting S1P biosynthesis could become a new way
to treat cancer, some studies found that the inhibition of S1P raised secondary malignancy [151,175].
A biospecific monoclonal antibody to S1P (S1P mAb) has been developed and investigated for its
role in tumorigenesis. The anti-S1P mAb substantially reduced tumor progression and in some cases
eliminated measurable tumors in murine xenograft and allograft models. Tumor growth inhibition
was attributed to antiangiogenic and antitumorigenic effects of the antibody [176]. The anti-S1P mAb
blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by
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VEGF and bFGF, and arrested tumor-associated angiogenesis [176]. In this study, SKOV3 cells were
used for ovarian cancer, but they are not cells from HGSOC, which accounts for about 70% of EOC
cases, with less than 30% of patients currently surviving more than five years after diagnosis with little
improvement in overall survival over the past 40 years [177–179]. Hence, the therapeutic significance
of targeting S1P in EOC warrants further studies.
In summary, the role of S1P in the pathogenesis of ovarian cancer remains unclear and
controversial and more studies are clearly required. Due to the multi-faceted nature of S1P’s roles and
signaling, targeting S1P signaling may be a double-edged sword.
2.5. Sphingosylphosphorylcholine (SPC)
SPC is an orthologue of LPC with a different backbone (a sphingoid base vs. a glycerol backbone).
The levels of SPC in EOC vs. non-malignant ascites is low: 71.5 ± 50.8 nM vs. 17.9 ± 10.1 nM,
respectively [28]. The levels of plasma SPC are also at nM range [45]. SPC is a potential calcium-release
inducer in EOC cells [25,26,29]. SPC also shows other cellular activities in EOC cells, including
regulation of IL-8 expression in EOC cells [94]. However, high concentrations (at µM level) of SPC
is very toxic to cells. SPC induces dendritic cells (DC) chemotaxis and stimulates the production of
IL-12 from DC [180,181]. However, the real physiological or pathological roles of SPC in EOC are still
very elusive.
3. Conclusions
The reciprocal interplay of cancer cells and TME is an indispensable prerequisite for tumor growth
and progression. Ovarian cancer, the most lethal of all gynecological malignancies, is characterized
by a unique TME that enables specific and efficient metastatic mechanisms/routes, impairs immune
surveillance, and mediates therapy resistance. More specifically, detached cancer cells—as well as
large numbers of T cells, TAMs, and other host cells—cooperate with resident host cells to support
tumor progression and immune evasion. The presence of the peritoneal fluid (ascites) enables more
efficient tumor-stromal cell interactions and the transcoelomic spread of tumor cells to other pelvic
and peritoneal organs. In particular, this fluid is rich in tumor-promoting soluble factors including
elevated LPLs, either in EV or non-EV forms. Several important future directions and unresolved
questions include, but are not limited to: development of standard and uniform methods for lipid
extraction and analyses; further characterization of LPL regulation (both production and degradation)
and their signaling mechanisms; development of strategies for cancer-specific targeting those tumor
promoting lipids; and conducting more studies on their extracellular associations in order to better
develop markers and targeting. Overall, it is critical to take TME into consideration to develop the
next generation of therapeutic strategies.
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